Chronic kidney disease: GLP-1 receptor agonists have shown renoprotective effects in clinical trials (FLOW trial with semaglutide), and orforglipron could be evaluated for similar indications
We serve patients from Dayton OH, Oakwood OH, Centerville OH, Kettering OH, Beavercreek OH, Yellow Springs OH, Airpark OH, Clifton OH, Byron OH, Oldtown OH, and surrounding areas.
gives the clinical context for when fat metabolism is relevant in treatment
In contrast, in 2018, the long-acting GIPGLP-1 co-agonist tirzepatide was found to have substantial glucose-lowering and weight loss properties, to a greater extent than that achieved by GLP-1R agonism with dulaglutide [68], findings replicated in Phase III trials comparing tirzepatide with semaglutide in people with type 2 diabetes [69]
Take 5ml daily